{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470478505
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[Clumping factor A]]
<!-- Clinical data -->
| tradename = Aurexis
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 521079-87-8
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = SBO7Q9G95R
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06054
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=6548 | H=10122 | N=1730 | O=2034 | S=44
| molecular_weight = 147.590 kg/mol
}}

'''Tefibazumab''' (named '''Aurexis''' but not approved) is a [[humanized monoclonal antibody]] for the treatment of severe infections with ''[[Staphylococcus aureus]]''. Possible indications include the treatment of ''S. aureus'' in a phase 2a patients with [[cystic fibrosis]]<ref>{{ClinicalTrialsGov|NCT00198289}}</ref> and of [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''S. aureus'']].<ref>{{Cite journal 
| pmid = 18221183 
| year = 2008 
| author1 = Pan | first2 = S. | first3 = A. 
| title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection 
| volume = 3 
| issue = 1 
| pages = 10–33 
| journal = Recent Patents on Anti-infective Drug Discovery 
| doi = 10.2174/157489108783413173 
| last2 = Lorenzotti 
| last3 = Zoncada
}}</ref>

It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal |author=John JF |title=Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection |journal=Curr. Opin. Mol. Ther. |volume=8 |issue=5 |pages=455–60 |year=2006 |pmid=17078388 |doi=}}</ref>

==See also==
* [[MSCRAMM]] (microbial surface components recognizing adhesive matrix molecules)

==References==
{{reflist}}

{{Monoclonals for infectious disease and toxins}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental drugs]]


{{antiinfective-drug-stub}}
{{monoclonal-antibody-stub}}